Abstract
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
COVID-19 Drug Treatment*
-
Humans
-
Medicare
-
Prescription Drugs / supply & distribution
-
Risk Assessment
-
United States
Substances
-
Antibodies, Monoclonal
-
Prescription Drugs